Ventyx Biosciences announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. The Phase 2a trial of VTX3232 in early Parkinson’s disease is expected to enroll approximately ten patients for a 28-day open-label treatment period. The trial’s primary endpoint is safety and tolerability. Other outcome measures include pharmacokinetics and relevant biomarkers in plasma and cerebrospinal fluid. The company expects to report topline results from this trial in 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences Announces Executive Financial Officer Changes
- Ventyx Biosciences Announces Departure of Chief Financial Officer
- Ventyx Biosciences announces departure of CFO Auster
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Ventyx Biosciences price target lowered to $14 from $15 at Canaccord
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue